The Biorevolution Podcast

Louise von Stechow
  • 0.0 (0)
  • LIFE SCIENCES
  • MONTHLY

The Biorevolution Podcast with Andreas Horchler and Louise von Stechow – father and daughter, journalist and biologist, talking about the technologies of the biorevolution. Can genetic engineering, synthetic biology, and artificial intelligence save humanity from disease, climate change, and overpopulation, or are these technologies the first step towards its downfall? Content and Editing: Louise von Stechow and Andreas Horchler Disclaimer: Louise von Stechow, Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics but do not claim to give medical, investment, or life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Image: Kelly Sikkema via Unsplash

  1. Nature’s origami– DNA nanotechnology

    19 HR AGO

    Nature’s origami– DNA nanotechnology

    DNA nanotechnology treats DNA not primarily as a carrier of genetic information, but as a programmable material. Based on the predictability of Watson–Crick base pairing, DNA nanotechnology allows researchers to encode specific structural information. DNA origami, in particular, is an interesting approach for reproducibly folding complex two- and three-dimensional DNA nano-objects. The potential of DNA origami structures shows their versatility, from biosensing and diagnostics to drug delivery, biomaterials, DNA data storage, and computing — even though the field is still at a comparatively early stage, with a number of interesting biotechs emerging. With DNA nanotechnology expert and science writer Marco Lolaico, we discuss the fascinating field of DNA nanotechnology, with structures from DNA smileys to DNA bunnies, to movable DNA machines. We ask Marco how big “huge” is through a nanotech lens, and whether we can expect a Nobel Prize for the technology. Find Marco here: https://www.linkedin.com/in/marco-lolaico/ Find his “Plenty of room” newsletter here: https://plentyofroom.beehiiv.com/ Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. References: 1. Nature Research Intelligence DNA Nanotechnology and Biomedical Applications. https://www.nature.com/research-intelligence/nri-topic-summaries/dna-nanotechnology-and-biomedical-applications-micro-2491 2. Seeman NC. Nucleic acid junctions and lattices. 1982. https://ui.adsabs.harvard.edu/link_gateway/1982JThBi..99..237S/doi:10.1016/0022-5193(82)90002-9 3. Rothemund PWK. Folding DNA to create nanoscale shapes and patterns. 2006. https://ui.adsabs.harvard.edu/link_gateway/2006Natur.440..297R/doi:10.1038/nature04586 4. Seeman NC, Sleiman HF. DNA nanotechnology. 2017. https://www.nature.com/articles/natrevmats201768 5. Zhan P et al. Recent Advances in DNA Origami-Engineered Nanomaterials. 2023. https://pubs.acs.org/doi/10.1021/acs.chemrev.3c00028 6. Dunn KE. The Business of DNA Nanotechnology: Commercialization of Origami and Other Technologies. 2020. https://www.mdpi.com/1420-3049/25/2/377 7. https://plentyofroom.beehiiv.com/p/molecular-hard-drives-dna-origami-rewrites-data-storage 8. Zhang C. Linked data storage using DNA origami nanostructures. 2025. https://www.nature.com/articles/s41467-025-66274-x 9. https://plentyofroom.beehiiv.com/p/dna-origami-boosts-anti-hiv-antibodies-vaccine-breakthrough 10. Romanov A. DNA origami vaccines program antigen-focused germinal centers. 2026. https://www.science.org/doi/10.1126/science.adx6291

    35 min
  2. From biohacking to healthcare- the growing pains of the longevity industry

    4 MAY

    From biohacking to healthcare- the growing pains of the longevity industry

    From Biohacking to Healthcare- the growing pain of the Longevity Industry Shownotes the BioRevolution podcast episode 48 For most of human history, “living longer” mainly meant not dying early but this has changed drastically with significantly increased life expectancy in the 20th century. This raises a new question: how can we live longer, individually and as a society, without simply shifting the burden into more years lived with chronic disease? Researchers are increasingly reframing the problem away from purely disease-by-disease fixes and toward the underlying biology of ageing that contributes to multiple conditions, such as cancer, cardiovascular, neurodegenerative, and metabolic disease. While the field is only beginning to untangle the complex, and likely multifactorial process of aging, a fledgling longevity industry has emerged around various hypotheses of aging mechanisms. The longevity industry spans therapeutics that target ageing-linked mechanisms, biomarkers and “clocks” that aim to measure biological ageing, and delivery models (clinics, digital platforms, consulting) that package measurement and interventions into services. In episode 48 of the BioRevolution podcast, we talk to Niko Hems, Growth Lead of Berlin-based longevity company YEARS and longevity writer and podcaster. Find Niko here: https://www.linkedin.com/in/niko-hems/ Find Niko’s “Beyond the Hype” course here: https://beyondthehype.kit.com/niko Find Niko’s podcast “Return on Health” with Miguel Medina here: https://open.spotify.com/show/3UmkL9XmmCGIs3jrxSV9CY?si=a74386952a2940f8 Find YEARS here: https://www.years.co/de Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Sources 1. https://ourworldindata.org/data-insights/global-average-life-expectancy-has-more-than-doubled-since-1900 2. https://www.nature.com/articles/s43587-024-00702-3 3. https://pubmed.ncbi.nlm.nih.gov/39418098/ 4. https://pubmed.ncbi.nlm.nih.gov/36599349/ 5. https://pubmed.ncbi.nlm.nih.gov/37118377/ 6. https://pharmaphorum.com/news/billionaire-backed-rejuvenation-start-up-altos-labs-launches-operations 7. https://blog.newlimit.com/p/newlimit-raises-130-million-series 8. https://pulse24.ai/news/2025/8/22/20/ai-boosts-cell-rejuvenation 9. https://www.biopharmatrend.com/news/fda-greenlights-first-human-trial-of-epigenetic-rejuvenation-therapy-for-vision-loss-1483/ 10. https://shiftbioscience.com/shift-bioscience-raises-16m-to-advance-ai-virtual-cell-platform-for-cell-rejuvenation/ 11. https://clock.bio/ 12. https://pubmed.ncbi.nlm.nih.gov/40563501/ 13. https://www.pharmiweb.com/press-release/2025-09-17/rubedo-life-sciences-announces-us-fda-clearance-of-ind-for-selective-gpx4-modulating-lead-drug-can 14. https://longevity.technology/news/senisca-raises-3-7-million-for-rapid-development-of-senotherapeutic-platform/ 15. https://dogagingproject.org/ 16. https://www.nature.com/articles/s41587-025-02932-1 17. https://link.springer.com/rwe/10.1007/978-3-030-22009-9_400 18. https://www.businesswire.com/news/home/20251216261885/en/Aeovian-Pharmaceuticals-Raises-%2455-Million-to-Advance-First-in-Class-Selective-mTORC1-Inhibitor-for-Tuberous-Sclerosis-Complex-Related-Epilepsy 19. https://pubmed.ncbi.nlm.nih.gov/34425083/ 20. https://www.biospace.com/press-releases/novo-nordisk-a-s-evoke-phase-3-trials-did-not-demonstrate-a-statistically-significant-reduction-in-alzheimers-disease-progression 21. https://pubmed.ncbi.nlm.nih.gov/37179335/ 22. https://www.businesswire.com/news/home/20250111808660/en/Immunis-Closes-%2425-Million-Series-A-1-Financing-Round

    37 min
  3. AI driven protein design- beyond nature's blueprint

    20 APR

    AI driven protein design- beyond nature's blueprint

    Nature has “gifted” us proteins that carry out a vast array of functions in cells, shaping the lives of all organisms, ecosystems, and ultimately the planet. In the age of synthetic biology, researchers are pushing beyond the catalogue of naturally evolved proteins by redesigning or even de novo designing proteins to make them more suitable for human goals—improving function, stability, specificity, manufacturability, or even creating entirely new capabilities. Artificial intelligence is becoming an important ally in transforming protein engineering from a trial-and-error process into a more predictive discipline, where deep learning models help predict the structure and function of a novel protein directly from its sequence. This enables faster generation and optimization of sequences for desired functions and reduces expensive and time-consuming wet-lab cycles. In this episode of the BioRevolution Podcast, Louise von Stechow and Andreas Horchler speak with Ingmar Schuster, AI expert and CEO of the protein design company Provolut, about the hopes, myths, and real potential of AI in protein design. Find Imgmar here: https://www.linkedin.com/in/ingmar-schuster/ Find Provolut here: https://provolut.bio/ Learn more about how they approach protein design for their clients here:https://provolut.bio/case-study-max-planck-insitute/ Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Sources 1. https://www.sciencedirect.com/science/article/pii/S2590093525000177 2. https://www.nature.com/articles/s44222-025-00349-8 3. https://link.springer.com/article/10.1007/s11427-024-2906-3 4. https://pubs.acs.org/doi/10.1021/acscentsci.3c01275 5. https://www.nature.com/articles/s41586-021-03819-2 6. https://www.nature.com/articles/s41587-024-02211-5 7. https://www.science.org/doi/10.1126/science.add2187 8. https://www.nature.com/articles/s41587-024-02123-4 9. https://pubmed.ncbi.nlm.nih.gov/36702895/ 10. https://www.profluent.bio/platform 11. https://provolut.bio/case-study-max-planck-insitute/ 12. https://provolut.bio/provolut-partners-with-ginkgo-bioworks/ 13. https://biopharma.ginkgo.bio/resources/blog/ginkgo-technology-network-launches-providing-an-integrated-rd-experience-with-capabilities-from-over-25-inaugural-partners

    34 min
  4. From Animals to Algorithms: How AI Brings Drug Testing Closer to Human Biology

    19 MAR

    From Animals to Algorithms: How AI Brings Drug Testing Closer to Human Biology

    Animal models have been the mainstay for testing hypotheses about human diseases and their treatment in academic research and drug development. However, these models raise ethical concerns and are costly and time-consuming. Most importantly, animal models often have low predictive power for the behavior of novel treatments in humans. Ethically, animal testing is arguably justifiable only if it can meaningfully predict outcomes in humans. Financially, committing millions of dollars and years of development to models with limited informative value is equally hard to defend. As governments and regulators, such as the US FDA, push to reduce animal testing, researchers from academia, pharma, and biotech are increasingly turning to new approach methodologies (NAMs) for preclinical and nonclinical testing. In this episode of the BioRevolution podcast, Louise von Stechow and Andreas Horchler discuss what is needed to shift from animal testing to NAM models which could be more meaningful for human biology. In particular, AI-based approaches offer a scalable alternative to animal testing that can make predictions based on a variety of data sources to provide a better understanding of human disease biology. Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow References 1. https://www.biopharmatrend.com/business-intelligence/from-animals-to-algorithms-how-ai-brings-drug-testing-closer-to-human-biology/ 2. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00298-9/fulltext 3. https://pubmed.ncbi.nlm.nih.gov/39805539/ 4. https://www.nature.com/articles/s41587-025-02690-0 5. https://www.nature.com/articles/d41586-025-03344-6 6. https://pubmed.ncbi.nlm.nih.gov/35865092/ 7. https://pubmed.ncbi.nlm.nih.gov/32868897/ 8. https://pubmed.ncbi.nlm.nih.gov/32324077/ 9. https://pubmed.ncbi.nlm.nih.gov/18357347/ 10. https://pmc.ncbi.nlm.nih.gov/articles/PMC9100373/ 11. https://pubmed.ncbi.nlm.nih.gov/31291566/ 12. https://aacrjournals.org/cancerdiscovery/article/8/9/1069/10253/Fundamental-Mechanisms-of-Immune-Checkpoint 13. https://www.nature.com/articles/s41746-025-02068-1 14. https://pubmed.ncbi.nlm.nih.gov/33356151/ 15. https://pubmed.ncbi.nlm.nih.gov/39836754/ 16. https://pubmed.ncbi.nlm.nih.gov/37676606/ 17. https://www.frontiersin.org/journals/artificial-intelligence/articles/10.3389/frai.2023.1269932/full 18. https://www.nature.com/articles/s41598-023-31169-8 19. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/vioxx-rofecoxib-questions-and-answers 20. https://onlinelibrary.wiley.com/doi/10.1002/pds.1207 21. https://www.nature.com/articles/s41467-023-42933-9

    30 min
  5. From Bench to Mic – Demystifying Science

    2 MAR

    From Bench to Mic – Demystifying Science

    In our complex world, science can be an important guiding thread for decision-making—both for policymakers and for individuals—on how to shape the health and wellbeing of society and individuals. But science often gets lost in translation, making it hard to distinguish facts from myths and to find truth within the complex picture of modern science. Good science communication is key to demystifying science and enabling science-based decision-making for everyone. In this episode of the BioRevolution podcast, we speak with Dr. Chandni Natalia Kumar, host of the Daily Dose of Honest Science podcast, a postdoc at the Biomedical Center Munich (LMU), and a proteomics enthusiast. Through her channel, Chandni shows what it means to communicate science honestly and accessibly in a world full of hype, myths, and self-optimization trends. We explore what it takes to bridge scientific research and science communication, and discuss the power of proteomics. Find Chandni here: https://www.linkedin.com/in/dr-chandni-natalia-kumar-628b7316a/ Find the Daily Dose of Honest Science podcast on YouTube: https://www.youtube.com/@DDHS_Podcast And Spotify: https://open.spotify.com/show/0CiSf91dGsvx6LX4NGGWmH?si=9439e1dcd01f4af4 Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow

    46 min
  6. Into the dark – finding meaning within the depth of our proteome

    5 FEB

    Into the dark – finding meaning within the depth of our proteome

    For decades, biology treated the human genome as a tidy instruction manual—genes neatly encoding proteins, surrounded by vast stretches of supposedly irrelevant DNA. As sequencing and molecular tools advanced, that picture fractured: scientists uncovered transposable elements, viral remnants, regulatory RNAs—and even unexpected, tiny non-canonical proteins, often called the “dark proteome.” Today, we know that much of this presumed “junk” DNA is biochemically active under specific conditions, forming an interconnected network of regulatory elements, mobile sequences, non-coding RNAs, and largely uncharacterized proteins. Some scientists believe this dark genomic layer acts as an adaptive reserve, helping genomes respond to stress, disease, and environmental change. In this episode Andreas Horchler and Louise von Stechow have a fascinating discussion with Dr. Sudhakaran Prabakaran, Associate Teaching Professor at Northeastern University, CEO of biotech NonExomics, and author of the upcoming book Eclipsed Horizons, which explores the dark genome, the proteome, evolution, and speculative futures for both humanity and the planet. Find Dr. Sudhakaran Prabakaran https://www.linkedin.com/in/sudhakaranprabakaran/ Find the Eclipsed Horizons https://sites.google.com/view/sudhakaranprabakaran/book Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow Image Unsplash via NASA Further Reading on the dark genome, proteome and beyond https://pubmed.ncbi.nlm.nih.gov/5065367/ 2. https://pmc.ncbi.nlm.nih.gov/articles/PMC2998295/ 3. https://www.genome.gov/about-genomics/educational-resources/fact-sheets/human-genome-project 4. https://www.nature.com/articles/538275a 5. https://www.nature.com/articles/512009e 6. https://pubmed.ncbi.nlm.nih.gov/7366731/ 7. https://pubmed.ncbi.nlm.nih.gov/15496913/ 8. https://www.sciencedirect.com/science/article/pii/S0960982212011542 9. https://plato.stanford.edu/entries/genomics/encode-project.html 10. https://www.researchgate.net/publication/269899103_Junk_or_functional_DNA_ENCODE_and_the_function_controversy 11. https://pubmed.ncbi.nlm.nih.gov/19213877/ 12. https://www.nature.com/articles/520615a 13. https://pmc.ncbi.nlm.nih.gov/articles/PMC11311765/ 14. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/pmic.202100211 15. https://pmc.ncbi.nlm.nih.gov/articles/PMC12701996/ 16. https://pmc.ncbi.nlm.nih.gov/articles/PMC9757701/ 17. https://www.nature.com/articles/ncomms6429 18. https://pubmed.ncbi.nlm.nih.gov/32139545/ 19. https://pubmed.ncbi.nlm.nih.gov/38176414/ 20. https://panspermia.org/mcclintocknrg2023.pdf 21. https://www.pnas.org/doi/10.1073/pnas.1912725116

    38 min
  7. Everything Everywhere All at Once: Mapping the Bigger Picture with Macroscopes

    19 JAN

    Everything Everywhere All at Once: Mapping the Bigger Picture with Macroscopes

    We’re living in the big data age, surrounded by personal, scientific, and societal data that could help us understand the world, make decisions, and even forecast what comes next. But complex systems don’t fit neatly into human intuition, and we can’t “see” meaning in massive datasets without help. That’s where macroscopes come in: software tools designed to make complexity interpretable, explorable and allow users to “make sense” out of big, complex data. In this episode of the BioRevolution podcast, Andreas Horchler and Louise von Stechow have Katy Börner as a guest. Katy is Professor of Engineering and Information Science at Indiana University, leads the international Human Reference Atlas, and is one of the founders and curators behind the long-running Places & Spaces: Mapping Science exhibit. Together they discuss why visualization + interpretation + communication of data matter just as much as data collection—and how macroscopes can help us make sense of our complex world. Find Katy here: https://cns-iu.github.io/katy https://www.bihealth.org/en/notices/prof-dr-katy-boerner-connects-anatomy-and-disease-with-the-multiscale-human-reference-atlas https://www.linkedin.com/in/katy-b%C3%B6rner-a03837/ Read more about data visualization and macroscopes here: https://scimaps.org/macroscopes https://bigthink.com/hard-science/macroscopes/ https://www.pnas.org/doi/10.1073/pnas.1807180116 https://dl.acm.org/doi/epdf/10.1145/1897852.1897871 https://dl.acm.org/doi/10.1145/3093338.3106387 https://mitpress.mit.edu/9780262014458/atlas-of-science/ https://mitpress.mit.edu/9780262028813/atlas-of-knowledge/ https://mitpress.mit.edu/9780262045957/atlas-of-forecasts/ https://mitpress.mit.edu/9780262049924/atlas-of-macroscopes/ https://mcn.edu/resources/meet-the-macroscopes/ https://journals.sagepub.com/doi/10.1177/0894439316643050 https://pubmed.ncbi.nlm.nih.gov/27032088/ https://pubmed.ncbi.nlm.nih.gov/24626916/ https://archive.org/details/macroscopenewwor0000rosn dagstuhl.de/21152/places-spaces/ Envisioning Intelligences exhibit call is at https://scimaps.org/call-for-submissions Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow

    40 min
  8. The Rare Lens: AI-based image recognition for rare disease diagnoses

    01/12/2025

    The Rare Lens: AI-based image recognition for rare disease diagnoses

    The Rare Lens: AI-based image recognition for rare disease diagnoses There are around 6000 rare diseases, which affect over 300 million people worldwide. Rare diseases are often difficult to diagnose, and people affected by a rare disease wait an average of five years or more for a correct diagnosis, which can be a heavy burden on patients and also hinders rare disease research and drug development. Artificial Intelligence (AI) can help address these diagnostic challenges. One promising approach is Next-Generation Phenotyping (NGP), which uses AI to detect disease-specific phenotypic patterns – such as distinct facial features – commonly associated with rare diseases, to support diagnosis and guide genetic testing. In the newest episode of the BioRevolution podcast, Andreas Horchler and Louise von Stechow spoke to two researchers from the University of Bonn working on next-generation phenotyping approaches: Dr. Adele Ruder, MSL for GestaltMatcher, and Dr. Behnam Javanmardi, Group Leader: AI for Rare Diseases and Head of Bone2Gene. We explored the potential of AI-driven diagnosis for rare diseases and what this could mean for people affected by rare diseases, their physicians, and researchers and drug developers in the rare disease space. Find Adele and GestaltMatcher here: https://www.linkedin.com/in/adeleruder/ https://www.gestaltmatcher.org/ Find Behnam and Bone2Gene here: https://www.linkedin.com/in/behnam-javanmardi/ https://bone2gene.org For further reading explore the following references: 1. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00056-1/fulltext https://www.nature.com/articles/s41431-024-01604-z 2. https://pubmed.ncbi.nlm.nih.gov/19627523/ 3. https://www.researchsquare.com/article/rs-2110140/v1 4. https://elifesciences.org/articles/02020 5. https://www.face2gene.com/ 6. https://facematch.org.au/home 7. https://cliniface.org/ 8. https://www.gestaltmatcher.org/ 9. https://bone2gene.org/ 10. https://www.nature.com/articles/s41591-018-0279-0 11. https://www.nature.com/articles/s10038-019-0619-z 12. https://www.nature.com/articles/s41588-021-01010-x 13. https://ieeexplore.ieee.org/document/10030218 14. https://www.nature.com/articles/s41431-025-01787-z https://doi.org/10.1007/s00112-024-02118-0 15. https://pubmed.ncbi.nlm.nih.gov/36779427/ 16. https://www.nature.com/articles/s41588-023-01469-w 17. https://www.medrxiv.org/content/10.1101/2023.06.06.23290887v4 18. https://www.nature.com/articles/s41599-024-02894-w 19. https://www.nature.com/articles/d41586-022-03050-7 20. https://www.nature.com/articles/s41746-024-01232-3 21. https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202414507 22. https://www.medrxiv.org/content/10.1101/2023.06.06.23290887v4.full.pdf Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow

    38 min
See All (49)

About

The Biorevolution Podcast with Andreas Horchler and Louise von Stechow – father and daughter, journalist and biologist, talking about the technologies of the biorevolution. Can genetic engineering, synthetic biology, and artificial intelligence save humanity from disease, climate change, and overpopulation, or are these technologies the first step towards its downfall? Content and Editing: Louise von Stechow and Andreas Horchler Disclaimer: Louise von Stechow, Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics but do not claim to give medical, investment, or life advice in the podcast. Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Image: Kelly Sikkema via Unsplash

Information

You Might Also Like